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ABSTRACT 
Background: Mediator complex (MED) proteins have a key role in transcriptional regulation, some 
interacting with the oestrogen receptor (ER). Interrogation of the METABRIC cohort suggested that 
MED7 may regulate lymphovascular invasion (LVI). Thus, MED7 expression was assessed in large 
breast cancer (BC) cohorts to determine clinico-pathological significance.  
Methods: MED7 gene expression was investigated in the METABRIC cohort (n=1980) and externally 
validated using bc-GenExMiner v4.0. Immunohistochemical expression was assessed in the 
Nottingham primary BC series (n=1280). Associations with clinicopathological variables and patient 
outcome were evaluated. 
Results: High MED7 mRNA and protein expression was associated with good prognostic factors: low 
grade, smaller tumour size, good NPI, positive hormone receptor status (p<0.001), and negative LVI 
(p=0.04) status.  Higher MED7 protein expression was associated with improved BC specific survival 
within the whole cohort and ER+/luminal subgroup.  Pooled MED7 gene expression data in the external 
validation cohort confirmed association with better survival, corroborating with the protein expression. 
On multivariate analysis, MED7 protein was independently predictive of longer BC specific survival 
in the whole cohort and Luminal A subtype (p<0.001).  
Conclusions: MED7 is an important prognostic marker in BC, particularly in ER+ luminal subtypes, 
associated with improved survival and warrants future functional analysis. 
Keywords: MED7, Breast Cancer, METABRIC, LVI, Luminal, ER+ 
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1. INTRODCUTION 
Breast cancer (BC) is a heterogeneous disease varying in presentation, morphological types, response 
to therapy and patient outcome. The development of high-throughput technologies to investigate 
genetic, epigenetic and proteomic changes has helped to unravel the complexity of BC biology (Dawson 
et al, 2013). Metastasis is the major cause of morbidity and mortality in BC patients and lymphovascular 
invasion (LVI), rather than blood vascular invasion seems to be the major mechanism involved in the 
early stages of metastases in BC (Mohammed et al, 2007). LVI has been shown to correlate with an 
increased histological grade and a poor prognosis. (Rakha et al, 2012). The molecular mechanisms of 
LVI are complex, involving multiple pathways, and remain hugely unknown (Karaman & Detmar, 
2014).  The METABRIC study investigated the genomic and transcriptomic data across 2,000 breast 
tumours, where associations between germline variants (CNVs and SNPs), somatic aberrations (CNAs) 
and alterations in gene expression were found. Further clustering analysis have identified 10 novel 
clusters (IntClust 1-10) which were associated with distinct CNAs and gene expression changes. The 
clusters have further divided the molecular subtypes and were associated with different clinical 
outcomes and drivers. In this study, a novel approach was utilised to unravel the molecular determinants 
of LVI. Global gene expression profiling data from the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) cohort (Curtis et al, 2012) was utilised to identify differentially 
expressed genes related to LVI status as determined by central histopathology review of H&E sections 
supplemented by D2-40 immunohistochemical analysis. Among top differentially expressed genes, the 
mediator protein MED7 was found to be inversely associated with LVI.  
The Mediator complex is a multi-subunit transcriptional coactivator complex required for the 
transcription of nearly all protein-coding genes (Gustafsson & Samuelsson, 2001). By its direct 
association with both signal-activated transcription factors and the RNA polymerase II transcription 
machinery, the mediator proteins function as a general integrator of regulatory signals that congregate 
on the promoters of protein-coding genes (Woychik & Hampsey, 2002). Disruption to Mediator 
subunits can affect many different cellular functions and fates, some of which could potentially be 
involved in carcinogenesis (Schiano et al, 2014). One of the Mediator subunits; MED7, plays an 
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important role in gonadal development and embryogenesis (Kwon et al, 1999). However, despite being 
a highly-conserved Mediator subunit, MED7 is not essential for viability across all species. A study 
investigating the functions of MED7 in Candida albicans found that a loss of MED7 did not lead to 
loss of viability (Tebbji et al, 2014). However, loss of MED7 has been reported to have a substantial 
impact on several cellular functions, in particular impairing metabolic functions. Overall, by deletion 
of different Mediator sub-modules, including MED7N (the N-terminal subunit of MED7) metabolic 
sensing, stress response, and certain amino-acid biosynthesis pathways are affected (Koschubs et al, 
2009). Gene expression profiling in gastrointestinal stromal tumours has shown that MED7 down-
regulation is associated with an increased tumour risk and could therefore potentially be a marker of 
favourable prognosis (Hur et al, 2010). Other members of the mediator complex such as MED1 have 
been reported to be associated with LVI in other series (Fidalgo et al, 2015) and hence MED7, another 
member of the Mediator complex, was deemed to be an interesting candidate to investigate. MED1 and 
MED24 have also been found to interact to mediate oestrogen receptor (ER) functions and regulate 
pubertal mammary gland and BC development (Hasegawa et al, 2012). Because of the association of 
other mediator proteins with ER, the role of MED7 in ER+ BCs was also explored, as ER+ BCs remain 
the most heterogeneous molecular group (Ciriello et al, 2013; Stingl & Caldas, 2007). Overall, this 
study aimed to investigate the clinico-pathological and biological significance of MED7 in BC 
including its role in LVI and hormonal receptor status. 
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2. MATERIALS AND METHODS 
2.1Differential gene expression and the selection of MED7:  
LVI status, as defined by morphology (H&E) supplemented with immunohistochemistry (D2-40 and 
CD34), was available for the Nottingham subset of the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) cohort and hence interrogated for differences between LVI+ 
and LVI- subgroups. Lymph node-positive samples were excluded from LVI- subgroup to avoid the 
confounding effect of undetectable LVI in these tumours. Data on differentially expressed genes 
between LVI+ and LVI- subgroups was obtained from microarray analysis data normalised to fit into a 
linear regression model (LIMMA: Linear models of microarray analysis). MED7 was ranked within the 
top 10% of these candidate genes as inversely (log fold change: -1.29) correlated with LVI (adjusted p 
value =0.0005). Chosen as a gene of interest, data from the whole (METABRIC) cohort (Supplementary 
Table 1; n=1980) (Curtis et al, 2012) was used to evaluate mRNA expression of MED7. [The 
METABRIC study provides data on genomic and transcriptomic profiling of breast cancer using the 
Affymetrix SNP 6.0 and Illumina HT-12 v3 platforms respectively. Detailed description of the 
experimental assays and analytical methods used have been described previously (Curtis et al, 2012; 
Silwal-Pandit et al, 2014)].  The assessment of the clinico-pathological impact of MED7 transcription 
and its associations with clinical outcome in the whole METABRIC series was performed by setting a 
cut-off point for the mRNA expression of MED7 at the median.  
2.2 External validation cohort 
For external validation, MED7 mRNA expression was interrogated through the BC-GenExMiner v4.0 
(Breast Cancer Gene-Expression Miner v4.0 online dataset (http:// bcgenex.centregauducheau.fr) 
(Jezequel et al, 2012), also used in other published studies (Aleskandarany et al, 2016a). This is 
composed of two statistical mining modules; the ‘prognostic module’, offering the possibility to 
evaluate the in vivo prognostic impact of candidate genes in BC, and the ‘correlation module’, to 
compute correlation coefficients between gene expressions or to find lists of correlated genes in BC. In 
this external validation, the prognostic module of the BC-GenExMiner, that evaluates the in vivo 
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prognostic impact of candidate genes in BC was utilised, using Cox model and Kaplan–Meier plot 
generation (Jezequel et al, 2012). Datasets with available MED7 expression in this online repository 
are catalogued in Supplementary Table 2.   
 
2.3 Patients and tumours  
The well-characterised Nottingham Tenovus Primary BC Series comprised the study population for 
protein expression (Supplementary Table 3). Briefly, this comprised of women aged 70 or less who 
presented to Nottingham City Hospital from 1988-1998 and received uniform treatment with a long-
term follow-up period. Patients’ clinicopathological profiles included histological phenotype, 
molecular subtypes, primary tumour size, histological grade, tumour stage, nodal status, Nottingham 
Prognostic Index (NPI), receptor status and other BC related biomarkers (Abd El-Rehim et al, 2005; 
Rakha et al, 2009). Outcome data including breast cancer-specific survival (BCSS), distant metastasis-
free interval (MFI) was maintained on a prospective basis. BCSS was defined as the interval (in months) 
from the date of primary surgery to the time of death because of BC, while MFI identified as the interval 
from the date of primary surgery to the appearance of distant metastasis.  
2.4 Western blotting 
For validation of MED7 Rabbit monoclonal antibody [EPR15410 (Abcam- Ab187146, Cambridge, 
UK] specificity, Western blotting was performed on whole cell lysates of MCF-7, SKBr3 and HEK293 
(obtained from the American Type Culture Collection; Rockville, MD, USA) cell lines using 1:1000 
dilution of the primary antibody, and fluorescent secondary antibodies (1:15000) (IR Dye 800CW 
donkey anti-rabbit and 680RD donkey anti-mouse, LI-COR Biosciences, UK). 5% milk (Marvel 
Original Dried Skimmed Milk, Premier Food Groups Ltd, St Albans, UK) was used for blocking. Mouse 
β-Actin (A5441, Sigma-Aldrich; Clone AC-15; Sigma, UK) at 1:5000 was used as a house-keeping 
protein. A protein ladder (Page Ruler Plus Prestained Protein Ladder, ThermoScientific, Waltham, MA, 
USA) was included. To visualise bands, fluorescence at wavelengths of 600, 700 and 800nm was used 
on a Licor Odyssey Fc with image studio 4.0 (LI-COR Biosciences). 
7 
2.5 Protein expression by Immunohistochemistry  
Tumour samples were arrayed onto tissue microarrays (TMAs) as previously described (Abd El-Rehim 
et al, 2005). IHC was performed on TMA sections using the Novolink Max Polymer Detection system 
(Leica, Newcastle, UK). In brief, sections were deparafﬁnised with xylene and rehydrated through 100 
% ethanol. Heat-induced retrieval of antigen epitopes was performed in citrate solution (pH 6.0). MED7 
staining was performed with a rabbit monoclonal antibody [EPR15410 (Abcam- Ab187146, 
Cambridge, UK], diluted (1:50), incubated for 60 min at room temperature. 3-3’ Diaminobenzidine 
tetrahydrochloride (Novolink DAB substrate buffer plus) was freshly prepared and used as chromogen. 
Counter staining was performed using Meyer’s haematoxylin for 6 min. Negative (omission of the 
primary antibody) and positive controls (anti-human-β-2-microglobulin; A0072, Dako) were included.   
 
The modified H-score method was used in assessing IHC staining, taking the staining intensity and 
percentage positivity into account (McCarty & McCarty, 1984). Briefly the percentages of positively 
stained tumour cells for each of these intensities were subjectively estimated. Staining intensity (0–3) 
was multiplied by percentage (0–100) and final scores were obtained, giving a range of 0 to 300.  High-
resolution digital images were generated via scanning the IHC stained slides (Nanozoomer; Hamamatsu 
Photonics, Welwyn Garden City, UK) at x20 magnification to facilitate the scoring of the TMA cores 
using a high-resolution (1920x1080) screen. Staining was double scored blindly by two researchers 
including a consultant histopathologist for ~25% cores to assess inter-observer concordance. 
Immunohistochemical staining and dichotomisation of the other biomarkers included in this study were 
as per previous publications (Aleskandarany et al, 2012; Aleskandarany et al, 2010a; Aleskandarany et 
al, 2011; Aleskandarany et al, 2010b; Barros et al, 2014; Elsheikh et al, 2008; Habashy et al, 2013; 
Rakha et al, 2007; Rakha et al, 2009) (Supplementary Table 4). BC molecular subtypes were defined 
based on the IHC profile as: Luminal A: ER+/HER2- Low Proliferation (Ki67<10%), Luminal B: 
ER+/HER2- High Proliferation (Ki67≥10%), HER2-positive class: HER2+ regardless of ER status, 
Triple Negative (TPN): ER-, PgR- and HER2-.  
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2.6 Statistical analysis  
IBM SPSS 22.0 (Chicago, IL, USA) software was used for statistical analysis. Univariate analysis was 
performed using the chi-squared test to evaluate the significance of the association between expression 
of the biomarkers and the clinicopathological parameters of the data, as well as other previously 
investigated biomarkers. Kaplan–Meier analysis with a log-rank test for significance was performed to 
assess BCSS and DFI survival differences. Multivariate Cox Regression analysis with adjustment of 
co-variates was fitted to test independence from standard prognostic factors in BC (stage, grade and 
LVI).  A p value of < 0.05 was considered significant.  
2.7 Ethics 
This study was approved by the Nottingham Research Ethics Committee 2 under the title ‘Development 
of a molecular genetic classification of breast cancer’. All samples from Nottingham used in this study 
were pseudo-anonymised and collected prior to 2006 and therefore under the Human Tissue Act 
informed patient consent was not needed. Release of data was also pseudo-anonymised as per Human 
Tissue Act regulations. 
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3 RESULTS 
3.1 MED7 mRNA expression and clinicopathological parameters:  
In the METABRIC cohort, high MED7 mRNA expression was observed in 981 cases (49.6%). High 
MED7 expression was associated with lower grade (p<0.0001), older age (p<0.0001) and 
good/excellent prognostic histological types (lobular and mucinous types (p=0.001). It was also 
associated with ER+ and progesterone receptor positive (PR+) tumours (both p<0.0001) and HER2-
negative status (p=0.00001; Table 1). When comparing the levels of MED7 mRNA expression in the 
intrinsic (PAM50) subtypes, significantly correlations were observed with luminal subtype tumours 
while the basal subtype showed the least expression levels (p<0.0001; Figure 1A). High MED7 mRNA 
expression was signiﬁcantly associated with IntClusts 3 and 8 (p<0.00001), clusters known to be 
enriched for luminal A like BCs associated with the most favourable clinical outcome in the 
METABRIC cohort. Overexpression of MED7 mRNA displayed significantly improved patients’ 
survival in the whole cohort (Figure 1B; p=0.025).  There was no association between MED7 mRNA 
expression and outcome in any of the PAM50 subtypes (Supplementary Figure 1A-D). As stated in the 
materials and methods, MED7 was inversely (log fold change: -1.29) correlated with LVI (adjusted p 
value =0.0005) when interrogated on the Nottingham subset of the cohort, that had available LVI data. 
 
3.2 MED7 expression and BC-biomarkers 
For IHC analysis on the Nottingham BC series, the specificity of the antibody was validated with a 
single specific band at the predicted size (32 kDa; Figure 1C). MED7 IHC showed nuclear staining with 
no cytoplasmic or stromal staining (Figure 1D-F).  The H-Scores of MED7 nuclear expression did not 
follow a normal distribution and hence the cut-off point for the MED7 H-score for low/high was set by 
the SPSS programme.at the median (H score > 130). All cut-offs were set before analysis. Of the 1280 
informative cores, 637 (49.8%) had high MED7 expression and 643 (50.2%) showed low expression. 
Similar to the mRNA observation, protein expression was also associated with good prognostic 
parameters. High nuclear MED7 expression was associated with smaller tumour size (p<0.0001), lower 
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grade (p<0.0001), lower mitotic scores (p<0.0001), higher tubule formation (p=0.0004) and less nuclear 
pleomorphism (p<0.0001). Lobular carcinomas showed signiﬁcantly higher expression of MED7 
(p=0.001) in comparison to ductal no special type and medullary subtypes (Table 2). Loss of MED7 
protein was correlated with positive LVI status (p=0.04). Overall, a relative lack of MED7 correlated 
with a poorer NPI (p <0.0001). 
 
On IHC, high nuclear MED7 expression showed signiﬁcant positive association with ER/PR status 
(p<0.0001), while negative association was observed with basal cytokeratins CK5/6 (p<0.001) and 
CK17 (p=0.003). Basal-like breast cancer is highly heterogeneous associated with high grade, poor 
patient outcome and CK5/6, and CK17 expression. MED7 expression was correlated with other 
characterized biomarkers on the series, some explored for their known association with ER+ luminal 
subtypes, viz coactivator-associated arginine methyltransferase 1, CARM1, an ERα coactivator (Al-
Dhaheri et al, 2011), the ER-chromatin interaction regulator Forkhead box protein A1, FOXA1 
(Hurtado et al, 2011) and RAS-like estrogen regulated growth inhibitor, RERG (Habashy et al, 2011). 
High expression of MED7 was positively associated with these luminal subtype related bio-markers: 
CARM1 (p=0.015), RERG (p=0.015) and FOXA1 (p<0.00001). Positive correlations were observed 
with cell cycle regulatory proteins such as GATA3 (p<0.0001), and STAT3 (p<0.0001), markers also 
known to be highly expressed in ER+ BC associated with favourable outcome (Aleskandarany et al, 
2016b; Voduc et al, 2008). Expression of histone modifiers which influence hormone responsive gene 
expression in BC (Nagarajan et al, 2015) were also positively associated with MED7 expression: viz. 
histone methylation modifiers at lysine (H3K4Me2: p=0.041; H4K12ac: p=0.004) and arginine residues 
(H4R3Me2; p=0.048) (Table 3). In contrast, negative correlations were observed with proliferation 
markers such as Ki67 (p=0.002), epithelial-mesenchymal transition markers such as N-cadherin 
(p<0.0001) and signaling pathway biomarkers like phosphatidylinositol-4,5-Bisphosphate 3-Kinase 
Catalytic Subunit Alpha (PIK3CA; p=0.001) and the epidermal growth factor receptor (EGFR; 
p=0.009).  
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3.3 MED7 and association with patient outcome 
High expression of MED7 protein was predictive of longer BCSS in the whole cohort (p<0.0001, 
HR=0.66; 95%CI: 0.54-0.81; Figure 2A), Luminal A (p=0.009, HR=0.42; 95%CI: 0.21-0.82; Figure 
2B) and Luminal B (p=0.014, HR=0.66; 95%CI: 0.47-0.92: Figure 2C) subtypes. There was no 
association between MED7 protein and outcome in TPN (p=0.442, HR=0.83; 95% CI: 0.51-1.3: Figure 
2D) and Her2+ subgroups (p=0.885, HR=1.0; 95% CI: 0.66-1.62: Figure 2E). However, MED7 
expression was not signiﬁcantly associated with MFI (p=0.056, HR=0.84; 95% CI: 0.70-1.0: Figure 
2F). In multivariate Cox regression analysis, MED7 protein was a predictor of better BCSS in the whole 
cohort and Luminal A subtypes. (p<0.01, Table 4).  
3.4 The prognostic impact of MED7 mRNA expression using bc-GenExMiner v 4.0 (Breast 
Cancer Gene-Expression Miner v 4.0).   
Targeted prognostic analyses for MED7 in LN negative BCs (n=34 data sets, 2431 patients) indicated 
that high levels of gene expression correlated with adverse event free survival (p=0.0085; HR=0.82; 
95% CI: 0.71-0.95, Figure 2G). As LVI status was not available for these cohorts, adverse event free 
survival served as a surrogate for the early metastatic phenotype. Expression analysis for MED7 with 
respect to hormone status (ER, PgR and HER2; n = 5461; Supplementary Figure 2A-C) corroborates 
with our analyses on the METABRIC/Nottingham cohorts that higher MED7 correlated with ER/PR 
positive status (p<0.0001) and but not HER2 status (p>0.05). Similarly, interrogation of the BC gene 
miner data revealed correlations with lower grade (n=3421; p<0.0001) and better NPI (n=1684; 
p=0.0021).  
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4. DISCUSSION  
Despite the plethora of biomarkers studied in BC, the molecular signatures underlying LVI in BC is 
undefined. Differential gene expression analysis in strictly defined LVI strata (morphology 
supplemented by IHC) in well validated BC cohorts would potentially provide the ideal opportunity to 
interrogate key molecules involved in generating the early metastatic phenotype. Using this approach 
utilising the METABRIC dataset, the mediator subunit MED7 was identified to be negatively related 
to LVI. To date, there has been relatively little research into MED7 compared with other Mediator 
subunits with respect to its potential role in BC. Of other mediator subunits, MED1 is required for 
estrogen receptor-mediated gene transcription and breast cancer cell growth (Zhang et al, 2013) and 
has also been implicated in vascular invasion (Fidalgo et al, 2015). On the other hand, recurrent MED12 
somatic mutations have been seen in fibroadenomas and phyllodes tumours (Lien et al, 2016). In 
contrast, the functional relationships of MED7 are little known. The aim of the study was to assess the 
potential associations between MED7 protein and various clinico-pathological variables in primary BC 
including hormonal receptor status and LVI to investigate its potential as a prognostic tool. 
 
High expression of both MED7 mRNA and protein were significantly associated with better behaving 
tumour characteristics, viz. low histological grade, older age, good NPI, ER+/PR+ tumours and 
histological subtypes of good prognosis. This is comparable to studies in other tumours where MED7 
down-regulation was significantly associated with increased risk of gastrointestinal stromal tumours 
(Koschubs et al, 2009). MED7 was preferentially positive in the lobular carcinomas in contrast to ductal 
or medullary-like tumours. Invasive lobular carcinomas are classically of lower grade with a low rate 
of mitosis and relatively uniform nuclei (Haltas et al, 2012; Rakha et al, 2008).  Many classical-type 
ILC tumours express ER and PR (Yu et al, 2011) both of which were significantly positively associated 
with MED7 expression. It was hypothesised that low-grade BCs develop through a different pathway 
from high-grade tumours which may involve alterations in expression of ER and altered genetic profiles 
in low-grade compared with high-grade tumours (Abdel-Fatah et al, 2008). This could implicate MED7 
as having a putative role in low-grade ER+ tumourigenic pathways. Moreover, high MED7 mRNA 
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expression level was signiﬁcantly associated with the ER positive integrative clusters 3 and 8 which 
had the most favourable clinical outcome in the METABRIC study (Curtis et al, 2012).  
 
There are several pathways by which ER is able to activate gene transcription. In the ER mediated 
pathway, dimerised ER directly binds to DNA sequences called Estrogen Response Elements (EREs) 
in relevant activated genes. However, ER is also known to use non-classical pathways to activate these 
genes either via Activator protein 1 (AP-1) or via Specificity protein 1 (Sp-1). MED7 acts as a co-
regulator for Sp1 activity (Ryu et al, 1999) and it is therefore possible that MED7 acts within the non-
classic Sp-1 pathway of ER gene activation. The biomarkers characterized on the Nottingham Primary 
series also serve as indicators of possible molecular networks in ER+ tumours where MED7 may be an 
interacting partner. Markers known to be overexpressed in luminal BC viz, CARM1 (Al-Dhaheri et al, 
2011), RERG (Finlin et al, 2001) and FOXA1 (Laganiere et al, 2005) revealed significant positive 
association with MED7 as also luminal CKs,  steroid receptors,  and cell cycle inhibitors (p21 and p27) 
which are  associated with good prognostic characteristics. MED7’s positive association with luminal 
markers indicate its role in better behaving tumours. However, the role of MED7 within the ER-related 
pathways may be quite complex, depending on the specific interacting partner. For example, in this 
study, MED7 expression was found to be negatively associated with EGFR expression. On one hand, 
it is known that EGFR overexpression in BC is associated with increased tumour size and worse patient 
outcomes and negatively correlates with estrogen receptor status (Masuda et al, 2012), explaining the 
observed negative association with MED7. However, it is also known that activation of EGFR by EGF 
triggers phosphorylation of MAPK and ERK, which in turn causes phosphorylation of Ser118 of the 
AF-1 domain of ERα, resulting in ER transactivation (ElTanani & Green, 1997). This transactivation 
can also occur via the PIK3CA and AKT pathway. Given the inverse relationship between MED7 and 
EGFR, MED7 may reduce EGFR-mediated ligand-independent ER activation. Its inverse relationship 
to PIK3CA is also another interesting link to investigate further within the milieu of intersecting ER 
regulating pathways as other studies indicate that PIK3CA mutations are strongly associated with ER-
positive tumours with better prognostic characteristics (Dumont et al, 2012).  ER+ BCs undergo 
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extensive chromatin remodeling and histone modifications for hormone-responsive gene expression. 
For instance, over expression of H4K12ac was associated with ER+ cells and these levels were further 
increased by estrogen treatment (Nagarajan et al, 2015).  
 
High levels of MED7 mRNA or protein was associated with a better prognosis in BC. On both univariate 
and multivariate analysis, MED7 expression was significantly associated with an improved long-term 
prognosis. In terms of the poor prognostic indicator, LVI (Lee et al, 1990), MED7 was negatively 
related with LVI, implying its protective role in BC. Given the strong association between MED7 and 
ER positive low grade luminal BCs, it is more likely that this correlation is a passenger effect rather 
than a driver event. Also, the overall correlation with good prognosis in the whole cohort seems to stem 
chiefly from MED7’s strong prognostic correlations in ER+ luminal A tumours. Though the prognostic 
effect of MED7 is not observed in ER-ve tumours, the prognostic value in ER positive BCs is potentially 
useful. Some ER positive tumours are known to recur in the long run; as MED7 is of prognostic 
significance over a long time span, this may help discriminate between good vs poorly performing ER 
positive tumours. In this study, the negative correlations with N-cadherin, CK5/6, and CK17 indicates 
that MED7 expression is not associated with aggressive BCs. N-cadherin gain is an epithelial 
mesenchymal transition (EMT) associated phenomenon contributing to BC aggressiveness (Hulit et al, 
2007) and tumour invasion and MED7 may be protective against BC cells acquiring an EMT prone 
phenotype. Cytokeratins were strongly associated with the high histological grade (III), ER−, PgR− 
status and worse patient outcome (Alshareeda et al, 2013) and their negative association with MED7 
further strengthens its role in non-basal type BC.   
 
There is an increasing focus towards the role of molecular approaches in the classification of BC as 
well as the use of epigenetics to devise new prognostic markers and predictive tools (Szyf, 2012). 
Recent research has indicated that epigenetic alterations such as DNA methylation and histone 
modifications play a role in the development of various cancers including BC, as these changes can 
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affect multiple gene networks and are able to influence many cellular processes related to 
tumorigenesis, (Dumitrescu, 2012). Histone modification methods, acetylation (Parthun, 2007) and 
methylation  (Xiao et al, 2003), in particular are known to impact on gene expression in cancer including 
BC (Elsheikh et al, 2009). MED7 was significantly positively associated with modified histone marks, 
H3K4Me2 and H4K12ac (methylation of lysine) and H4R3Me2 (methylation of arginine. High 
H4R3Me2, with which MED7 was significantly associated, was associated with good prognosis and a 
longer disease free survival and with luminal-type tumours and hormone receptor expression (Elsheikh 
et al, 2009). Positive vascular invasion, associated with lower MED7 levels, is also known to be 
associated with low levels of other histone marks like H4K16ac (Elsheikh et al, 2009);  It may be 
conjectured that MED7 may be involved in some part of the histone modification process or is recruited 
to genes which have been modified by histones to confer a better overall prognosis. 
This study revealed and confirmed that, MED7 was associated with good prognostic characteristics and 
better long-term survival outcome in BC. Morphologically, it is significantly associated with invasive 
lobular cancers. Over-expression of MED7 particularly appears to play a significant role in ER+ 
Luminal subtype of breast cancer and given its association with multiple ER related markers, further 
functional assessment is necessary to reveal the specific role played by this mediator protein in these 
ER positive tumours. The current study suggests a multi-functional role of MED7 in invasive BC 
biology, and validates the utility of multi-platform approaches (global expression profiling, 
complemented by immunohistochemistry) in prognostic biomarker discovery.  
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Titles and Legends to Figures 
Figure 1. A) MED7 mRNA and PAM50 subtypes, B) MED7 mRNA vs BCSS in the whole cohort,  
C) Western Blotting analysis using MED7 Rabbit monoclonal antibody [EPR15410]. Intensity levels 
of staining are shown: D) low, E) strong and F) negative expression (x200 magnification).   
 
Figure 2. Kaplan-Meier survival plots for MED7 nuclear expression:  A) MED7 vs BCSS in all 
cases; B) MED7 vs BCSS in Luminal A; C) MED7 vs BCSS in Luminal B; D) MED7 vs BCSS in 
TPN; E) MED7 vs BCSS in HER2+; F) MED7 vs MFI in all cases and G) Targeted prognostic 
analyses for MED7 via the BC gene miner in ER+ node negative patients using Breast Cancer Gene-
Expression Miner v4.0. 
 
Supplementary Figure 1: MED7 gene expression and breast cancer patient outcome in different 
BC sub groups. A) MED7 mRNA vs BCSS in Luminal A tumours, B) MED7 mRNA vs BCSS in 
Luminal B tumours, C) MED7 mRNA vs BCSS in Triple Negative tumours and D) MED7 mRNA vs 
BCSS in HER2+ tumours.  
 
Supplementary Figure 2: MED7 gene expression and its association, using Breast Cancer Gene-
Expression Miner v4.0.  A) ER status, B) PR status and C) HER2 status. 
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Table 1: Associations between MED7 mRNA expression and clinicopathological variables in
the METABRIC cohort
Clinicopathological
Criteria
MED7 mRNA
expression χ2 (p Value)
Low (%) High (%)
Age at Diagnosis
≤50 251 (59.3) 172 (40.7) 17.35(<0.00001)
>50 723 (47.9) 787 (52.1)
Tumour Size (cm)
≤2.0 423 (49.4) 434 (50.6)
>2.0 558 (50.7) 542 (49.3) 0.36 (0.554)
Histological Grade
1 62 (36.5) 108 (63.5)
2 374 (48.6) 396 (51.4) 21.68 (<0.0001)
3 521(54.8) 429 (45.2)
Tumour Type
Ductal 866 (51.0) 833 (49)
Lobular* 62 (42.2) 85 (57.8) 19.39 (0.001)
Medullary-like 26 (81.2) 6 (18.8)
Special type * 19 (38.8) 30 (61.2)
Miscellaneous 12 (57.1) 9 (42.9)
NPI
Good Prognostic
Group 313 (46.0) 367(54.0)
Moderate Prognostic
Group 580 (52.8) 519(47.2) 7.95 (0.019)
Poor Prognostic
Group 104 (52.3) 95(47.7)
PAM50 subtype
Luminal A 297(41.4) 421(58.6)
Luminal B 179 (36.7) 309 (63.3) 165.80 (<0.00001)
Basal 242 (73.8) 86 (26.2)
Her2 164 (68.3) 76 (31.7)
Normal like 112 (56.6) 86 (43.4)
IntClustMemb
IntClustMemb 1 62 (44.6) 77 (55.4)
IntClustMemb 2 32 (44.4) 40 (55.6)
IntClustMemb 3 107 (36.9) 183 (63.1)
IntClustMemb 4 183 (53.4) 160 (46.6)
IntClustMemb 5 117 (61.6) 73 (38.4) 120.96 (<0.00001)
IntClustMemb 6 39 (45.9) 46 (54.1)
IntClustMemb 7 106 (55.8) 84 (44.2)
IntClustMemb 8 105 (35.1) 194 (64.9)
IntClustMemb 9 77 (53.1) 68 (46.9)
IntClustMemb 10 169 (75.1) 56 (24.9)
ER
Negative 312 (71.2) 126 (28.8) 97.43 (<0.00001)
Positive 665 (44.4) 832 (55.6)
PR
Negative 566 (60.3) 373 (39.7) 69.69 (<0.00001)
Positive 431(41.5) 608 (58.5)
HER2
Negative 844 (48.8) 887 (51.2) 15.03 (0.0001)
Positive 153 (61.9) 94 (38.1)
Significant p values are highlighted in bold.
Table 3: Associations of nuclear MED7 IHC expression
and other tissue biomarkers within the Nottingham BC series.
BC
Biomarker
MED7 Nuclear Staining
χ2 (p value) 
Low (%) High (%)
ER
Negative 208 (62.8) 123 (37.2)
28.120 (<0.0001)
Positive 429(45.9) 506 (54.1)
PgR
Negative 305 (58.7) 215 (41.3)
22.014 (<0.0001)
Positive 316 (45.1) 385 (54.9)
HER2
Negative 517 (49.3) 532 (50.7)
3.22 (0.085)
Positive 98 (56.6) 75 (43.4)
CK5/6
Negative 385 (50.4) 379 (49.6)
12.895 (<0.001)
Positive 99 (66.4) 50 (33.6)
CK17
Negative 376 (51.8) 350 (48.2)
9.012 (0.003)
Positive 72 (67.3) 35 (32.7)
STAT3
Negative 356 (57.7) 261 (42.3)
44.140 (<0.0001)
Positive 77(32.4) 161 (67.6)
GATA3
Negative 343(62.4) 207 (37.6)
41.045 (<0.0001)
Positive 59 (34.5) 112 (65.5)
EGFR
Negative 468(48.4) 498(51.6)
7.052 (0.009)
Positive 149(57.8) 109(42.2)
PIK3CA
Negative/Low 99(43.2) 130(56.8)
13.287 (0.001)Medium 115(47.7) 126(52.3)
High 270(57.0) 204(43.0)
N Cadherin
Negative 106 (37.7) 175 (62.3)
31.728 (<0.0001)
Positive 355 (58.0) 257 (42.0)
Ki67
Low 179 (44.8) 221 (55.2)
10.305 (0.002)
High 328 (55.1) 267 (44.9)
H3K4Me2
Negative 82 (54.3) 69 (45.7)
4.591(0.041)
Positive 115 (43.4) 150(56.6)
H4K12ac
Negative 89 (56.7) 68 (43.3) 8.654 (0.004)
Positive 107 (41.8) 149 (58.2)
H4R3Me2
Negative 113 (55.1) 92 (44.9)
4.233 (0.048)
Positive 115(45.5) 138(54.5)
RERG
Negative 326(53.4) 284(46.6)
5.893 (0.015)
Positive 89(43.6) 115(56.4)
CARM1
Negative 127(59.1) 88(40.9)
6.057 (0.015)
Positive 85(46.7) 97(53.3)
FOXA1
Negative 278(63.5) 160(36.5)
41.623 (<0.0001)
Positive 154(40.8) 223(59.2)
Significant p values are highlighted in bold.
Table 2: Relationship between nuclear MED7 protein (IHC) and
clinicopathological parameters of the Nottingham BC series.
Clinicopathological
Criteria
MED7 Nuclear Staining
χ2 (p Value) 
Low (%) High (%)
Age at Diagnosis
≤50 220 (48.6) 233 (51.4)
0.781(0.381)
>50 423(51.1) 404 (48.9)
Tumour Size (cm)
≤2.0 274 (44.1) 348 (55.9)
19.09 (<0.0001)
>2.0 366 (56.3) 284 (43.7)
Histological Grade
1 82 (39.8) 124 (60.2)
49.341(<0.0001)2 174 40.8) 252(59.2)
3 383 (60.2) 253 (39.8)
Tubule formation
1 26 (39.4) 40 (60.6)
15.589 (0.0004)2 185 (43.8) 237 (56.2)
3 406 (54.6) 338 (45.4)
Nuclear Pleomorphism
1 8 (26.7) 22 (73.3)
29.894 (<0.0001)2 195 (41.9) 270 (58.1)
3 413 (56.2) 322 (43.8)
Mitotic score
1 164 (39.8) 248 (60.2)
43.005 (<0.0001)2 110 (44.4) 138 (55.6)
3 343 (60.0) 229 (40.0)
Tumour Type
Ductal 551 (51.6) 516 (48.4)
20.575 (0.001)
Lobular* 41 (35.3) 75 (64.7)
Medullary-like 22 (75.9) 7 (24.1)
Special type 22 (42.3) 30 (57.7)
**Lymph Node Stage
I 398 (51.1) 381 (48.9)
1.853 (0.603)II 191 (49.6) 194 (50.4)
III 50 (48.1) 54 (51.9)
NPI
Good Prognostic
Group 157(40.6) 230 (59.4)
23.546 (<0.0001)ModeratePrognostic Group 358 (53.1) 316 (46.9)
Poor Prognostic
Group 125 (59.2) 86 (40.8)
IHC-validated LVI
Negative 319 (47.5) 352 (52.5)
4.10 (0.04)
Positive 196 (54.1) 166 (45.9)
*Tumour type p value reflects association between MED7 and lobular tumours
**Lymph node stages 1, 2 and 3 refer to the lymph node staging score incorporated in the
Nottingham Prognostic Index, routinely used for breast cancer prognostication: 1: refers to no
lymph nodes being involved; 2 refers to 1-3 lymph nodes positive and 3: >3 lymph nodes
positive.
Significant p values are highlighted in bold.
Table 4: Univariate and multivariate analysis: Effects of nuclear MED7 expression, LN
Stage, Grade and LVI.
Variable Univariate
Multivariate
HR 95%CI p value HR 95%CI p value
Whole cohort
Stage 2.1 1.9-2.4 <0.001 1.8 1.5 – 2.1 <0.001
Grade 2.3 2.0-2.6 <0.001 1.9 1.6 – 2.3 <0.001
LVI 2.1 1.8-2.6 <0.001 1.5 1.2 – 1.9 0.001
MED7 0.7 0.5-0.8 <0.001 0.7 0.6-0.9 0.007
Luminal A
Stage 2.3 1.6-3.4 <0.0001 1.9 1.1-3.3 0.025
Grade 2.4 1.6-3.6 <0.0001 1.4 0.8-2.5 0.204
LVI 1.0 0.5-2.0 0.937 0.8 0.4-1.9 0.663
MED7 0.4 0.2 – 0.8 0.012 0.5 0.2 – 0.9 0.028
Luminal B
Stage 1.8 1.5-2.2 <0.001 1.8 1.3-2.5 <0.001
Grade 1.8 1.4-2.3 <0.001 2.9 0.9-8.7 0.015
LVI 2.0 1.5-2.7 <0.001 1.5 0.9-2.5 0.062
MED7 0.7 0.4-0.9 0.015 0.9 0.6-1.4 0.074
TPN
Stage 1.7 1.3--2.2 <0.001 1.6 1.1-2.3 0.022
Grade 1.8 1.4-2.3 0.964 1.9 0.8-2.0 0.812
LVI 2.2 1.4-3.3 <0.001 1.7 0.9-3.0 0.085
MED7 0.8 0.5-1.3 0.444 0.9 0.5-1.5 0.673
HER2
Stage 2.4 1.8-3.1 <0.001 1.8 1.2-2.7 0.002
Grade 2.9 0.9-8.7 0.057 1.5 0.9-2.7 0.141
LVI 2.1 1.3-3.3 0.003 2.4 1.3-4.3 0.003
MED7 1.0 0.6-1.6 0.885 1.0 0.6-1.6 0.868
Significant p values are highlighted in bold.
Table Legends:
Table 1: Associations between MED7 mRNA expression and clinicopathological variables in
the METABRIC cohort; Significant p values are highlighted in bold.
Table 2: Relationship between nuclear MED7 protein (IHC) and clinicopathological
parameters of the Nottingham BC series. *Tumour type p value reflects association between
MED7 and lobular tumours ; **Lymph node stages 1, 2 and 3 refer to the lymph node staging
score incorporated in the Nottingham Prognostic Index, routinely used for breast cancer
prognostication: 1: refers to no lymph nodes being involved; 2 refers to 1-3 lymph nodes
positive and 3: >3 lymph nodes positive. Significant p values are highlighted in bold.
Table 3: Associations of nuclear MED7 IHC expression and other tissue biomarkers within
the Nottingham BC series. Significant p values are highlighted in bold.
Table 4: Univariate and multivariate analysis: Effects of nuclear MED7 expression, LN
Stage, Grade and LVI. Significant p values are highlighted in bold.
Supplementary Table1: Summary of clinico-pathological characteristics for the
METABRIC cohort.
Supplementary Table2: Datasets (Study code and reference) included in the online analysis
for MED7 on the BC-GenExMiner v4.0 (Breast Cancer Gene-Expression Miner v4.0 online
dataset).
Supplementary Table 3: Summary of clinicopathological data for the Nottingham Tenovus
Primary Series
Supplementary Table 4: Biomarkers characterised in the Nottingham Tenovus Primary
Series with antibodies used, source, dilutions and cut-offs.
